Arca
Skip to content
Tools
Tools

Pneumococcal disease

Drug research and approvals for pneumococcal disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 36 studies of pneumococcal disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.

  • Recruiting worldwide: 36
  • Trials authorized in Canada: 11
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 36 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

The 10 newest of 11; search them all in Canada trials
May 22, 2026A phase 3, randomized, double-blinded trial to evaluate the safety and tolerability of a multivalent pneumococcal conjugate vaccine in healthy infantsPF-07872412 (25-VALENT pneumococcal conjugate (25VPNC) vaccine)PfizerOngoing
Dec 20, 2023A phase 3, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of…V116 (pneumococcal 21-VALENT conjugate vaccine)Merck & Co. (MSD)Ongoing
Sep 20, 2023A phase 2 multicenter, randomized, active-controlled, observer-blind, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of a…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25)Inventprise Inc.Ongoing
Dec 16, 2022A phase 3, randomized, double-blind, active comparator-controlled clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in…V116 / Vaxneuvance / Pneumovax 23Merck & Co. (MSD)Ongoing
Jul 8, 2022A phase 3 clinical study to evaluate the safety, tolerability,and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or olderV116 / Vaxneuvance (PCV15) / Pneumovax 23 (PPSV23)Merck & Co. (MSD)Ongoing
Sep 25, 2020Safety and immunogenicity of a pneumococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy toddlers and infantsSP0202 - multivalent pneumococcal conjugate vaccine (PCV) / Prevnar13SanofiPending
Apr 15, 2020A phase 3, randomized, double-blind trial to evaluate the safety of a 20-valent pneumococcal conjugate vaccine in healthy infantsPF-06482077 (20-VALENT pneumococcal conjugate vaccine [20VPNC])PfizerClosed
Jul 3, 2019A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in…V114Merck & Co. (MSD)Ongoing
Nov 28, 2018A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants…V114Merck & Co. (MSD)Ongoing
Jul 16, 2018A phase 3, multicenter, randomized, double-blind, active comparatorcontrolled study to evaluate the safety, tolerability, and immunogenicity of V114 followed…V114Merck & Co. (MSD)Ongoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.